Hand-foot syndrome after administration of tyrosinkinase inhibitors;Hand-foot syndrom po podání inhibitorů tyrozinkinázové aktivity

Klinicka Onkologie

Volumn 23, Issue 5, 2010, Pages 300-305

  Bednaříková, Dagmar ^a   Kocak I ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Hand foot syndrome; Skin; Sorafenib; Sunitinib; Targeted therapy; Toxicity; Tyrosinkinase inhibitor

Indexed keywords

SORAFENIB; SUNITINIB;

CANCER PATIENT; CANCER THERAPY; DRUG DOSE REDUCTION; HAND FOOT SYNDROME; HUMAN; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SYNDROME;

EID: 78149338573     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy Dermatologica 1974; 148(2): 90-92.
2. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib. a randomised controlled trial. Lancet 2006; 368(9544): 1329-1338.
3. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24(3): 457-461.
4. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19(11): 1955-1961.
5. Yang CH, Lin WC, Chuang CK et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy Br J Dermatol 2008; 158(3): 592-596
6. Chu D, Lacouture ME, Fillos T et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008, 47(2): 176-186.
7. Chu D, Lacouture ME, Weiner E et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma a meta-analysis. Clin Genitourin Cancer 2009; 7(1): 11-19.
8. Autier J, Escudier B, Wechsler J et al Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor Arch Dermatol 2008; 144(7): 886-892.
9. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1(4): 225-234.
10. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published. May 28, 2009 (v 4.03: June 14, 2010). Available from: http://evs.ncinih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11. pdf.
11. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13(9): 1001-1011.
12. Lee WJ, Lee JL, Chang SE et al Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161(5): 1045-1051.
13. Beldner M, Jacobson M, Surges GE et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007; 12(10): 1178-1182.
14. Lai SE, Kuzel T, Lacouture ME. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25(3): 341-343.
15. Thompson DS, Greco FA, Spigel DR et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. J Clin Oncol 2006; 24 (Suppl 18): 4594.
16. Yang CH, Chuang CK, Hsieh JJ et al. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 2010; 9(3): 459-470.
17. Robert C, Mateus C, Spatz A et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009, 60(2): 299-305.
18. Robert C, Escudier B. Cutaneous side effects of multikinase inhibitors used in renal cell cancer. Oncology News International 2007; 5: 1-20.
19. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12(4): 426-437.
20. Azad NS, Aragon-Ching JB, Dahut WL et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15(4): 1411-1416.
21. Jain L, Gardner ER, Figg WD et al. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 2010; 30(1): 52-56.
22. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16(11): 3537-3541.
23. Keohan M, D'Adamo D, Qin L et al. Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). J Clin Oncol 2007; 25(Suppl 18): 10061.
24. Kampmann KK, Graves T, Rogers SD. Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions Cancer 1989; 63(12): 2482-2485
25. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(26) 4293-4300.
26. Cheng AL, Kang YK, Chen Z et al Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25-34
27. Jain L, Sissung TM, Danesi R et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 29: 95.
28. Vincenzi B, Santini D, Russo A et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15(1): 85-92.
29. Gressett SM, Stanford BL, Hardwicke F Management of hand-food syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12(3): 131-141.
30. Lee S, Lee S, Chun Y et al. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. J Clin Oncol 2007; 25: 9007.
31. Mortimer JE, Lauman M, Tan B et al. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Practice 2003; 9: 161-166.
32. Holečková P. Studie PRESSO 1. Prevence hand - foot skin reaction = kožní reakce na dlaních a chodidlech při terapii Nexavarem (sorafenibem) a korelace stupně hand - foot skin reaction a hladiny neopterinu. Multicentrická randomizovaná nezaslepená prospektivní studie Data u autorky.